Segment reporting - Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting | ||||
| Research and development expense | $ 22,616 | $ 20,458 | $ 41,891 | $ 36,822 |
| Stock-based compensation | 5,245 | 4,752 | 9,625 | 9,697 |
| Depreciation and amortization | 2,696 | 3,000 | 5,424 | 6,072 |
| Total operating expenses | 34,476 | 31,986 | 65,537 | 60,894 |
| Segment One | ||||
| Segment Reporting | ||||
| Personnel | 9,569 | 10,283 | 18,815 | 20,148 |
| Stock-based compensation | 5,245 | 4,752 | 9,625 | 9,697 |
| General & administrative | 4,032 | 3,538 | 8,366 | 7,860 |
| Depreciation and amortization | 2,696 | 3,000 | 5,424 | 6,072 |
| Other (gain)/loss, net | 37 | (246) | 40 | (232) |
| Total operating expenses | 34,476 | 31,986 | 65,537 | 60,894 |
| Drug creation program and platform | Segment One | ||||
| Segment Reporting | ||||
| Research and development expense | 6,045 | 5,289 | 12,128 | 9,295 |
| External preclinical and clinical development | Segment One | ||||
| Segment Reporting | ||||
| Research and development expense | $ 6,852 | $ 5,370 | $ 11,139 | $ 8,054 |
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|